Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Inclusion Criteria:

• Participants who have completed 52-week Treatment Period as per protocol in aNovartis study of secukinumab in PMR patients (the "core study" - StudyCAIN457C22301), AND

• who have experienced a relapse during the treatment-free follow-up period ofthe core study, AND

• who have not been on rescue treatment.

• The participant would potentially derive benefit from secukinumab, and the benefitoutweighs the risk, based on the investigator's judgement.

Exclusion Criteria:

• Use of prohibited medications, as specified in the protocol

• History of ongoing, chronic or recurrent infectious disease (i.e., humanimmunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), activetuberculosis infection (TB))

• History of lymphoproliferative disease or any known malignancy or history ofmalignancy of any organ system within the past 5 years (except for basal cellcarcinoma or actinic keratosis that have been treated with no evidence of recurrencein the past 3 months carcinoma in situ of the cervix or non-invasive malignant colonpolyps that have been removed).

• Live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zostervaccines) within 6 weeks prior to Baseline

• Subjects whose participation in the extension study could expose them to an unduesafety risk